MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025018776

Медицинская библиотека · Blood advances · 2026

Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy.

Shen Guomin, Song Dan, Li Shixin, Chen Xuejie, Richter Catherine E, Dong Shixia, Guo Yiming, Liu Hongli, Shen Yan, Hao Zhenyu, Stafford Darrel W, Shavit Jordan A, Cao Qing, Tie Jian-Ke

СтатьяПеревод в очереди

Аннотация

Oral anticoagulants such as warfarin, which function as vitamin K antagonists (VKAs), have long been central to anticoagulation therapy. Warfarin inhibits vitamin K epoxide reductase (VKOR), thereby restricting the availability of reduced vitamin K and impairing γ-carboxylation and activation of vitamin K-dependent clotting factors (VKDCFs). However, warfarin's clinical use is hindered by a narrow therapeutic index and marked interindividual variability, largely attributable to genetic variation in VKOR, yet it remains the only oral anticoagulant option for clinical conditions such as antiphospholipid antibody syndrome. γ-Glutamyl carboxylase (GGCX), the enzyme that directly modifies VKDCFs, represents an attractive but largely unexplored target for anticoagulation. Using a cell-based high-throughput screen of the Maybridge Hit-Finder compound library (comprising 14 400 drug-like molecules), we identified 21 compounds that inhibited γ-carboxylation of VKDCFs. Subsequent gene-deficient cell-based assays and in vitro enzymatic characterization revealed that compound HF13141-H5 selectively and potently inhibits GGCX activity, with nanomolar half-maximal inhibitory concentrations. Molecular docking with the recently resolved GGCX structure suggested that HF13141-H5 mimics the binding of reduced vitamin K, and site-directed mutagenesis confirmed the critical hydrogen bond with residue N290 within the substrate-binding pocket. Importantly, HF13141-H5 maintained full inhibitory potency against VKOR variants associated with warfarin resistance and demonstrated robust anticoagulant activity in a zebrafish laser-induced endothelial injury model. In summary, we describe the discovery and mechanistic characterization of HF13141-H5 as the first small-molecule GGCX inhibitor. By directly targeting GGCX, HF13141-H5 presents a promising strategy for developing next-generation anticoagulants that could overcome the limitations of warfarin, such as genetic variability and resistance.

Для цитирования: Shen Guomin, Song Dan, Li Shixin, Chen Xuejie, Richter Catherine E, Dong Shixia, Guo Yiming, Liu Hongli, Shen Yan, Hao Zhenyu, Stafford Darrel W, Shavit Jordan A, Cao Qing, Tie Jian-Ke. Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2025018776.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.